RxDoctor Payments Data

Mark Peacock, MD

Pulmonary Disease · Nashville, TNNPI 1427052224

Payments from drug & device makers

$1,018in general payments, 2019–2025

Across 43 payments — averaging $23.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$494
  • Medtronic$180
  • Genentech USA, Inc.$144
  • GSK$60
  • Insmed, Inc.$32
  • Philips North America LLC$31
  • plus $77 from 5 others

What the payments were for

  • Food & beverage$96795%
  • Education$505%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,018 in reported general payments places this provider in the 30th percentile of 339 pulmonary disease providers in Tennessee.

See all pulmonary disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$23,360
Medicare patients
89
Services billed
244

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter196$148,298
Breztri AerosphereBudesonide/Glycopyr/Formoterol31$24,685
Breo ElliptaFluticasone/Vilanterol36$24,653
Spiriva RespimatTiotropium Bromide15$11,839
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr24$10,225
Advair DiskusFluticasone Propion/Salmeterol15$8,150
Roflumilast80$4,781
Albuterol Sulfate HfaAlbuterol Sulfate115$3,435
Wixela InhubFluticasone Propion/Salmeterol21$2,977
Ventolin HfaAlbuterol Sulfate18$2,305
Azithromycin85$845
Montelukast Sodium64$804
Ipratropium Bromide22$628
Prednisone115$453
Omeprazole16$209

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$60$183,177256 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 339 pulmonary disease providers in Tennessee.

Other pulmonary disease in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →